Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CRIS
CRIS logo

CRIS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Curis Inc (CRIS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.580
1 Day change
-6.32%
52 Week Range
3.130
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Curis Inc (CRIS) is not a strong buy for a beginner, long-term investor at this time. The stock shows bearish technical indicators, poor financial performance, and no significant positive catalysts. Given the investor's preference for long-term stability, it's better to hold off on investing in CRIS until there are signs of improvement in financials or technical trends.

Technical Analysis

The stock's MACD is slightly positive but contracting, RSI is neutral at 48.145, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support is at 0.503, and resistance is at 0.732. The stock has a 60% chance to increase slightly in the next day or week but is expected to drop by -7.49% over the next month.

Positive Catalysts

  • NULL identified. No recent news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

  • The stock price dropped significantly (-13.64%) in the regular market session. Financial performance in Q4 2025 showed a sharp decline in revenue (-65.98% YoY), net income (-301.25% YoY), and EPS (-198.40% YoY).

Financial Performance

In Q4 2025, Curis Inc's revenue dropped to $1,138,000 (-65.98% YoY), net income dropped to $19,356,000 (-301.25% YoY), and EPS dropped by -198.40% YoY. Gross margin also declined slightly to 72.41%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data on analyst ratings or price target changes available.

Wall Street analysts forecast CRIS stock price to rise
2 Analyst Rating
Wall Street analysts forecast CRIS stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.617
sliders
Low
5
Averages
11
High
17
Current: 0.617
sliders
Low
5
Averages
11
High
17
Evercore ISI
Outperform
downgrade
$40 -> $38
AI Analysis
2026-01-05
Reason
Evercore ISI
Price Target
$40 -> $38
AI Analysis
2026-01-05
downgrade
Outperform
Reason
Evercore ISI lowered the firm's price target on Caris Life Sciences to $38 from $40 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have "set the stage for a 2026 Tools play," the analyst tells investors. In MedTech, the firm's survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes "have bears watching," the analyst added.
Canaccord
Kyle Mikson
Hold
maintain
$28 -> $30
2025-12-22
Reason
Canaccord
Kyle Mikson
Price Target
$28 -> $30
2025-12-22
maintain
Hold
Reason
Canaccord analyst Kyle Mikson raised the firm's price target on Caris Life Sciences to $30 from $28 and keeps a Hold rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026. They beleve Caris Life Sciences could be attractive with continued momentum or a material share price pullback.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CRIS
Unlock Now

People Also Watch